Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCC1727 in combination with benmelstobart/olaparib/topotecan for advanced solid tumors
NCT07371663Phase 2Recruiting
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TCC1727 in non-small cell lung cancer (NSCLC), endometrial cancer (EC), ovarian cancer, gastric cancer (GC), gastroesophageal junction cancer, sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
TCC1727
03
Conditions
non-small cell lung cancer (NSCLC)endometrial cancer (EC)ovarian cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07371663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371663.